• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胃食管反流病患者使用质子泵抑制剂的经济学评价:一项系统综述

Economic evaluation of proton pump inhibitors in patients with gastro-oesophageal reflux disease: a systematic review.

作者信息

Tabaeian Seidamir Pasha, Moeini Sajad, Rezapour Aziz, Afshari Somayeh, Souresrafil Aghdas, Barzegar Mohammad

机构信息

1Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.

Department of Health Services Management, School of Health Management & Information Sciences, Iran University of Medical Sciences, Tehran, Iran

出版信息

BMJ Open Gastroenterol. 2024 Dec 20;11(1):e001465. doi: 10.1136/bmjgast-2024-001465.

DOI:10.1136/bmjgast-2024-001465
PMID:39797661
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11664378/
Abstract

OBJECTIVES

Our aim was to systematically review the cost-effectiveness of proton pump inhibitor (PPI) therapies and surgical interventions for gastro-oesophageal reflux disease (GORD).

DESIGN

The study design was a systematic review of economic evaluations.

DATA SOURCES

We searched PubMed, Embase, Scopus, and Web of Science for publications from January 1990 to March 2023. Only articles published in English were eligible for inclusion.

ELIGIBILITY CRITERIA

Studies were included if they were full economic evaluations comparing PPIs with surgical or alternative therapies for GORD. Excluded were narrative reviews, non-peer-reviewed articles, and studies not reporting cost-effectiveness outcomes.

DATA EXTRACTION AND SYNTHESIS

Two reviewers independently extracted data on study design, comparators, time horizon, and cost-effectiveness outcomes. The quality of studies was assessed using the Joanna Briggs Institute (JBI) checklist for economic evaluations.

RESULTS

A total of 25 studies met the inclusion criteria. Laparoscopic Nissen fundoplication (LNF) was found to be cost-effective in long-term horizons, while PPIs were preferred for short- to medium-term outcomes. Differences in healthcare settings and methodological approaches influenced the study findings.

CONCLUSIONS

Strategic purchasing decisions for GORD treatment should consider the time horizon, healthcare setting, and cost structures. LNF may provide better long-term value, but PPIs remain effective for managing symptoms in the short term.

STUDY REGISTRATION

PROSPERO, CRD42023474181.

摘要

目的

我们的目的是系统评价质子泵抑制剂(PPI)疗法和手术干预对胃食管反流病(GORD)的成本效益。

设计

研究设计为对经济评估的系统评价。

数据来源

我们在PubMed、Embase、Scopus和Web of Science中检索了1990年1月至2023年3月的出版物。仅纳入以英文发表的文章。

纳入标准

如果研究是比较PPI与GORD的手术或替代疗法的全面经济评估,则纳入研究。排除叙述性综述、非同行评审文章以及未报告成本效益结果的研究。

数据提取与综合

两名评审员独立提取关于研究设计、对照、时间范围和成本效益结果的数据。使用乔安娜·布里格斯研究所(JBI)经济评估清单评估研究质量。

结果

共有25项研究符合纳入标准。发现腹腔镜下尼森胃底折叠术(LNF)在长期来看具有成本效益,而PPI在短期至中期结果方面更受青睐。医疗环境和方法学方法的差异影响了研究结果。

结论

GORD治疗的战略采购决策应考虑时间范围、医疗环境和成本结构。LNF可能提供更好的长期价值,但PPI在短期内仍能有效控制症状。

研究注册

PROSPERO,CRD42023474181。

相似文献

1
Economic evaluation of proton pump inhibitors in patients with gastro-oesophageal reflux disease: a systematic review.胃食管反流病患者使用质子泵抑制剂的经济学评价:一项系统综述
BMJ Open Gastroenterol. 2024 Dec 20;11(1):e001465. doi: 10.1136/bmjgast-2024-001465.
2
Cost-effectiveness of proton pump inhibitors versus laparoscopic Nissen fundoplication for patients with gastroesophageal reflux disease: a systematic review of the literature.质子泵抑制剂与腹腔镜 Nissen 胃底折叠术治疗胃食管反流病的成本效益比较:文献系统评价。
Surg Endosc. 2011 Oct;25(10):3127-34. doi: 10.1007/s00464-011-1689-y. Epub 2011 Apr 13.
3
Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial).腹腔镜手术与药物治疗胃食管反流病的临床和经济评价:多中心随机试验(REFLUX 试验)的 5 年随访。
Health Technol Assess. 2013 Jun;17(22):1-167. doi: 10.3310/hta17220.
4
The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis.Stretta手术与质子泵抑制剂及腹腔镜下Nissen胃底折叠术治疗胃食管反流病的成本效益分析
Can J Gastroenterol. 2008 Jun;22(6):552-8. doi: 10.1155/2008/765458.
5
Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults.成人胃食管反流病(GORD)的腹腔镜胃底折叠术与药物治疗对比
Cochrane Database Syst Rev. 2015 Nov 5;2015(11):CD003243. doi: 10.1002/14651858.CD003243.pub3.
6
Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study.腹腔镜胃底折叠术与药物治疗胃食管反流病的成本效益研究
BMJ. 2009 Jul 14;339:b2576. doi: 10.1136/bmj.b2576.
7
Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease.比较腹腔镜尼氏胃底折叠术与质子泵抑制剂维持治疗胃食管反流病的短期成本效益和长期成本分析
Br J Surg. 2005 Jun;92(6):700-6. doi: 10.1002/bjs.4933.
8
Cost-utility of laparoscopic Nissen fundoplication versus proton pump inhibitors for chronic and controlled gastroesophageal reflux disease: a 3-year prospective randomized controlled trial and economic evaluation.腹腔镜 Nissen 胃底折叠术与质子泵抑制剂治疗慢性和控制型胃食管反流病的成本-效用分析:一项 3 年前瞻性随机对照试验和经济评估。
Value Health. 2011 Mar-Apr;14(2):263-73. doi: 10.1016/j.jval.2010.09.004.
9
A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD.药物治疗或手术(腹腔镜胃底折叠术)治疗胃食管反流病的成本效益比较。
Pharmacoeconomics. 2007;25(10):829-41. doi: 10.2165/00019053-200725100-00003.
10
The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial.胃食管反流病患者中微创手术的有效性和成本效益——一项英国合作研究。反流试验。
Health Technol Assess. 2008 Sep;12(31):1-181, iii-iv. doi: 10.3310/hta12310.

本文引用的文献

1
Diagnosis and treatment of patients with gastroesophageal reflux disease - a systematic review of cost-effectiveness and economic burden.胃食管反流病患者的诊断和治疗——成本效益和经济负担的系统评价。
BMC Health Serv Res. 2024 Nov 6;24(1):1351. doi: 10.1186/s12913-024-11781-8.
2
The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System.引入RefluxStop治疗难治性胃食管反流病对意大利医疗保健系统的经济影响。
Pharmacoecon Open. 2024 Nov;8(6):935-943. doi: 10.1007/s41669-024-00521-7. Epub 2024 Aug 27.
3
Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease.
新型非主动植入装置治疗难治性胃食管反流病的成本效益分析。
J Med Econ. 2023 Jan-Dec;26(1):603-613. doi: 10.1080/13696998.2023.2201063.
4
Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China.沃克与质子泵抑制剂在中国治疗反流性食管炎的成本效益分析
Ann Transl Med. 2022 Apr;10(8):480. doi: 10.21037/atm-22-1722.
5
Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan.反流性食管炎的治疗策略,包括钾离子竞争性酸阻滞剂:日本的成本效益分析
J Gen Fam Med. 2021 Feb 21;22(5):237-245. doi: 10.1002/jgf2.429. eCollection 2021 Sep.
6
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.PRISMA 2020 声明:系统评价报告的更新指南。
Int J Surg. 2021 Apr;88:105906. doi: 10.1016/j.ijsu.2021.105906. Epub 2021 Mar 29.
7
Cost-effective Analysis of Proton Pump Inhibitors in Long-term Management of Gastroesophageal Reflux Disease: A Narrative Review.质子泵抑制剂在胃食管反流病长期管理中的成本效益分析:一项叙述性综述
Hosp Pharm. 2020 Oct;55(5):292-305. doi: 10.1177/0018578719893378. Epub 2019 Dec 18.
8
Anti-reflux Surgery Versus Proton Pump Inhibitors for Severe Gastroesophageal Reflux Disease: A Cost-Effectiveness Study in Korea.抗反流手术与质子泵抑制剂治疗重度胃食管反流病:韩国的一项成本效益研究
J Neurogastroenterol Motil. 2020 Apr 30;26(2):215-223. doi: 10.5056/jnm19188.
9
Costs of bleeding on long-term antiplatelet treatment without routine co-prescription of proton-pump inhibitors.长期抗血小板治疗无质子泵抑制剂常规联合治疗时的出血成本。
Int J Stroke. 2021 Aug;16(6):719-726. doi: 10.1177/1747493019879658. Epub 2019 Sep 30.
10
Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.胃食管反流病中“沃诺拉赞优先”策略与“埃索美拉唑或雷贝拉唑优先”策略的成本-效用分析。
J Gastroenterol. 2019 Dec;54(12):1083-1095. doi: 10.1007/s00535-019-01609-2. Epub 2019 Aug 8.